Daiichi Sankyo US’ Post

https://lnkd.in/gf2RXecS Enhertu belongs to a class of therapies called antibody-drug conjugates (ADC) and comprises a monoclonal antibody - in this case trastuzumab (also known as Herceptin) - chemically linked to a cell-killing chemotherapy drug. The drug, sold under the brand name #Enhertu, originally won U.S. approval in late 2019 as a third-line treatment for HER-2-positive breast #cancer patients, and the fresh approval opens the treatment across multiple HER2-expressing solid tumors #monoclonalantibodies #Oncology

The drug, sold under the brand name Enhertu, originally won U.S. approval in late 2019 as a third-line treatment for HER-2-positive breast cancer patients, and the fresh approval opens the treatment across multiple HER2-expressing solid tumors. Enhertu belongs to a class of therapies called antibody-drug conjugates (ADC) and comprises a monoclonal antibody - in this case trastuzumab (also known as Herceptin) - chemically linked to a cell-killing chemotherapy drug. #Oncology #moniclonalantibody #Oncology #Enhertu https://lnkd.in/gf2RXecS

🎉 Exciting News! 🎉 Our latest scientific article titled "Third-Line Treatment Patterns in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis of Real-World Data in Canada" in collaboration with Knight Therapeutics has just been published in the Journal of Pharmacy & Pharmaceutical Sciences! Our study reveals a lack of consensus in Canada for post-second-line treatment of HER2+ metastatic breast cancer, highlighting significant delays in accessing new treatments in this indication. This underscores the need for a modernized system for faster drug access and reimbursement in Canada. Read more below and leave us a comment to discuss how we can improve treatment access for cancer patients in Canada. #breastcancer #publication #RWE #RealWorldEvidence #cancerresearch

Exactis’ state of the art database provides remarkable opportunities using real world date; to study natural history of particular patient sub-groups or to provide ghost controls that are matched to experimental drug treated patients, or to help transform patient support or special access programs into data to support accelerated approval of new and effective drugs. This paper demonstrates that Exactis can use this DB to generate Canada wide data, and that it can be augmented by additional data retrieval.

Pfizer's latest results from the ECHELON-3 trial herald a breakthrough for patients affected by the aggressive Diffuse Large B-cell Lymphoma (DLBCL). The study shows a beacon of hope, with the Adcetris combination significantly improving overall survival rates. Evaluating the Adcetris trio against lenalidomide and rituximab plus placebo, the findings are set to be a cornerstone in global DLBCL treatment. The company plans to discuss regulatory submission with the FDA, potentially leading to an eighth indication for ADCETRIS. This landmark achievement promises new treatment possibilities for patients battling this aggressive form of cancer. #Oncology #Lenalidomide #Rituximab #Pfizer #CancerResearch #DLBCL #Adcetris #FDA

Exactis’ state of the art database provides remarkable opportunities using real world date; to study natural history of particular patient sub-groups or to provide ghost controls that are matched to experimental drug treated patients, or to help transform patient support or special access programs into data to support accelerated approval of new and effective drugs. This paper demonstrates that Exactis can use this DB to generate Canada wide data, and that it can be augmented by additional data retrieval.

Ending Oncology's Toxic Relationship With High Chemotherapy Doses One-size-fits-all anticancer therapeutic dosing will fade away over the next 10 years. Truly personalized Nof1 diagnostics to inform on-label / off-label FDA-approved anticancer agents—especially for those hosting advanced cancer and beyond effective NCCN standard of care guidance—must also focus on minimally effective dosing, not maximum tolerated dosing. And pharma must learn to be comfortable with that. #precisionmedicine #precisiononcology #personalizedoncology #Nof1

GSK announced that the #FDA has expanded approval for #dostarlimab (#Jemperli) with #chemotherapy for all adults with primary advanced or recurrent #endometrial #cancer. This treatment, now including patients with MMRp/MSS #tumors, has shown a 31% reduction in death risk and significant improvements in survival rates.  Hesham A. Abdullah, MD, MSc, Senior VP, Global Head Oncology, R&D, GSK, said: “Jemperli plus chemotherapy is the first and only #immuno-#oncology regimen to show significant and meaningful improvement in overall survival for adult patients with primary advanced or recurrent endometrial cancer regardless of biomarker status. We are thrilled this option is now available for more patients.” #endometrialcancer https://lnkd.in/dGJu4uEP

Advancements in Oncology: Key Data From the 2024 ASCO Annual Meeting: The 2024 American Society. ofClinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, highlighted significant advancements across various oncology disciplines. #finance #pharmacy #lifesciences

Atossa Therapeutics, Inc. (NASDAQ:ATOS) told investors it ended 2023 with $88.5 million in cash and cash equivalents and no debt as it advanced its investigational therapeutic (Z)-endoxifen, which is targeting #BreastCancer and other breast conditions. Key clinical developments from the fourth quarter and in 2024 to date included the company fully enrolling two Phase 2 studies, its Karisma trial of  (Z)-endoxifen in premenopausal women with measurable breast density and its I-SPY trial of (Z)-endoxifen as a neoadjuvant treatment for patients with newly diagnosed estrogen receptor-positive breast cancer.  More at #Proactive #ProactiveInvestors #NASDAQ #ATOS #Biotech #Biopharmaceutcials #Oncology http://ow.ly/wmJN105o7H4